Clinical Trials Browser

NIH × Sunitinib × CNS × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03641326 2022-04-19

Sunitinib in Sarcomas of the Central Nervous System

Phase 2 Terminated

5 enrolled 14 charts

Brain Neoplasms, Gliosarcoma

NCT00499473 2016-02-29

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Phase 2 Completed

31 enrolled 6 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00923117 2015-09-30

Sunitinib to Treat Recurrent Brain Cancer

Phase 2 Terminated

87 enrolled 11 charts

Brain Neoplasms, Glioblastoma, Glioma

NCT01462695 2015-08-27

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Phase 2 Completed

30 enrolled 8 charts

Familial ependymoma, Astrocytoma, Oligodendroglioma

NCT00387920 2014-01-28

Sunitinib in Treating Young Patients With Refractory Solid Tumors

Phase 1 Completed

CNSOther solid neoplasm

Central Nervous System Metastases